PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Abroad (travel likely)RecruitingPHASE3

Conditions

Androgen Axis Suppression · Prostatectomy · Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Rush MD Anderson, Chicago, Illinois, United States
Contact: Study coordinator (Dian Wang, MD) · dian_wang@rush.edu
Contact: Principal Investigator (Dian Wang, MD)
University of Kansas Medical Center, Kansas City, Kansas, United States
Contact: Study coordinator (Xinglei Shen, MD) · xshen@kumc.edu
Contact: Principal Investigator (Xinglei Shen, MD)
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Paul Nguyen, MD) · paul_nguyen@dfci.harvard.edu
Contact: Principal Investigator (Paul Nguyen, MD)
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Marisa Kollmeier, MD) · kollmeim@mskcc.org
Contact: Principal Investigator (Marisa Kollmeier, MD)
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Karen Hoffman, MD) · khoffman1@mdanderson.org · 713-563-2339
Contact: Principal Investigator (Karen Hoffman, MD)

Study leads

Karen Hoffman, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov